A REAL-WORLD ANALYSIS OF TREATMENT PATTERNS FOR FIRST-LINE IMMUNOTHERAPIES AMONG DANISH PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) AND PD-L1 EXPRESSION $50%

被引：0
|
作者：
Clugston, D. M. [1 ]
Beck, C. [2 ]
Bjerregaard, B. K. [3 ]
Kristensen, E. S. [4 ]
机构：
[1] Roche Pharmaceut AS, Copenhagen, Denmark
[2] Roche Pharmaceut AS, Copenhagen 84, Denmark
[3] IQVIA Denmark, Copenhagen, Denmark
[4] IQVIA, Copenhagen, Denmark
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
RWD53
引用
收藏
页码：S514 / S514
页数：1
相关论文
共 50 条
  • [41] Real-world outcomes of PD-L1 inhibitors combined with thoracic radiotherapy in the first-line treatment of extensive stage small cell lung cancer
    Jianfeng Peng
    Lemeng Zhang
    Liping Wang
    Hui Feng
    Dongmei Yao
    Rui Meng
    Xiaomei Liu
    Xiaohua Li
    Ningbo Liu
    Bingxu Tan
    Zhaoqin Huang
    Shanshan Li
    Xiangjiao Meng
    Radiation Oncology, 18
  • [42] Time on Treatment of First-Line PD-1 Inhibitor Monotherapy for Metastatic Non-Small Cell Lung Cancer Patients: Real-World Experience Data
    Apter, L.
    Moser, S. Sharman
    Chandwani, S.
    Chen, X.
    Shalev, V.
    Chodick, G.
    Siegelmann-Danieli, N.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S920 - S920
  • [43] Recent Patterns across Therapy Lines and Real-World Survival Post First Line PD-L1 Treatment for Small Cell Lung Cancer
    Borghaei, H.
    Shaw, J.
    Pundole, X.
    Balasubramanian, A.
    Anderson, E.
    Bebb, G.
    Jiang, T.
    Pastel, M.
    Martinez, P.
    Ramalingam, S.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S377 - S378
  • [44] Real-world treatment patterns before and after receiving PD-l1 test results in patients with advanced non-small cell lung cancer (aNSCLC)
    Ge, Wenzhen
    Antonia, Scott
    Wu, Ning
    Pouliot, Jean-Francois
    Dietz, Hilary
    Jalbert, Jessica
    Quek, Ruben Gw
    Harnett, James
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 111 - 112
  • [45] Real-world PD-L1 testing and distribution of PD-L1 tumor expression by immunohistochemistry assay type among patients with metastatic non-small cell lung cancer in the United States
    Velcheti, Vamsidhar
    Patwardhan, Pallavi D.
    Liu, Frank Xiaoqing
    Chen, Xin
    Cao, Xiting
    Burke, Thomas
    PLOS ONE, 2018, 13 (11):
  • [46] The real-world comparison of non-small cell lung cancer survival outcomes depending on immunotherapy treatment and PD-L1 expression level
    Ondrusova, Martina
    Suchansky, Martin
    Svidova, Sona VaNDOR
    Chowaniecova, Gabriela
    Mrinakova, Bela
    Sekeresova, Monika
    Juskanic, Dominik
    Ondrus, Dalibor
    Senitko, Michal
    NEOPLASMA, 2024, 71 (05)
  • [47] Real-World Costs of Adverse Events in First-Line Treatment of Metastatic Non-Small Cell Lung Cancer
    Engel-Nitz, Nicole M.
    Johnson, Michael P.
    Bunner, Scott H.
    Ryan, Kellie J.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2020, 26 (06): : 729 - 740
  • [48] Real-World Prevalence of PD-L1 Expression Among Tumor Samples From Patients With Non-Small-Cell Lung Cancer
    Gelatti, Ana C. Z.
    Cordeiro de Lima, Vladmir C.
    Freitas, Helano
    Werutsky, Gustavo
    Gaiger, Ana Maria
    Klock, Clovis
    Viola, Patricia P.
    Shiang, Christina
    de Macedo, Mariana P.
    Lopes, Lisandro F.
    De Marchi, Pedro
    Albino da Silva, Eduardo Caetano
    Moura, Fernando
    Borges, Giuliano
    Zaffaroni, Facundo
    Nunes Filho, Paulo Ricardo
    Araujo, Luiz H.
    Mascarenhas, Eldsamira
    Mathias, Clarissa
    Barrios, Carlos
    Zukin, Mauro
    CLINICAL LUNG CANCER, 2020, 21 (06) : E511 - E515
  • [49] Real-world prevalence of PD-L1 expression in locally advanced or metastatic non-small cell lung cancer (NSCLC): The global, multicentre EXPRESS study
    Dietel, M.
    Savelov, N.
    Salanova, R.
    Micke, P.
    Bigras, G.
    Hida, T.
    Piperdi, B.
    Burke, T.
    Khambata-Ford, S.
    Deitz, A.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : S74 - S75
  • [50] Real-world data analysis of PD-L1 expression and overall survival (OS) in advanced non-small cell lung cancer (aNSCLC)
    Staib, J.
    Sudarsanam, S.
    Byfield, S. Dacosta
    Kennedy, C.
    Weiss, L.
    ANNALS OF ONCOLOGY, 2019, 30 : 27 - 27
12345